Clinical Trial Update: Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) [Phase 2]

View source ↗

Summary

This update presents safety and efficacy data from a Phase 2 study of pembrolizumab (Keytruda) in children and young adults with classical Hodgkin lymphoma (MK-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING